Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis

Open access
Noth, Imre, Anstrom, Kevin J., Calvert, Sara Bristol, de Andrade, Joao, Flaherty, Kevin R., Glazer, Craig, Kaner, Robert J., Olman, Mitchell A. · 2012 · American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: Animal and human studies support the importance of the coagulation cascade in pulmonary fibrosis. Objectives: In a cohort of subjects with progressive idiopathic pulmonary fibrosis (IPF), we tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in FVC. Methods: This was a double-blind, randomized, placebo-controlled trial of warfarin targeting an international normalized ratio of 2.0 to 3.0 in patients with IPF. Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 weeks. International normalized ratios were monitored using encrypted home point-of-care devices that allowed blinding of study therapy. Measurements and Main Results: The primary outcome measure was the composite outcome of time to death, hospitalization (nonbleeding, nonelective), or a 10% or greater absolute decline in FVC. Due to a low probability of benefit and an increase in mortality observed in the subjects randomized to warfarin (14 warfarin versus 3 placebo deaths; P = 0.005) an independent Data and Safety Monitoring Board recommended stopping the study after 145 of the planned 256 subjects were enrolled (72 warfarin, 73 placebo). The mean follow-up was 28 weeks. Conclusions: This study did not show a benefit for warfarin in the treatment of patients with progressive IPF. Treatment with warfarin was associated with an increased risk of mortality in an IPF population who lacked other indications for anticoagulation. Clinical trial registered with www.clinicaltrials.gov (NCT00957242).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201202-0314oc

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. de Andrade, 2011, Hemostasis and fibrinolysis in the pathogenesis of lung injury and repair, 315

Cited by

See all 500

Metadata

Authors
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A.
Affiliations
  • University of Chicago (US)
  • Duke University (US)
  • University of Alabama, Birmingham, Alabama
  • National Jewish Health (US)
  • The University of Texas Southwestern Medical Center (US)
  • Cornell University (US)
  • Cleveland Clinic (US)
Corresponding author
Noth, Imre
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2012-07-01
Volume
186
Issue
1
Pages
88-95
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2055609841
Cited by
463
References
22
Citations by year
2026: 4 · 2025: 14 · 2024: 16 · 2023: 16 · 2022: 26 · 2021: 28 · 2020: 30 · 2019: 27 · 2018: 30 · 2017: 49 · 2016: 49 · 2015: 56 · 2014: 37 · 2013: 57 · 2012: 20
FWCI
43.81
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Chicago Community Trust
  • National Heart, Lung, and Blood Institute (U10HL080509, U10HL080543, U10HL080571, U10HL080383, K24HL111316, U10HL080513, U10HL080685, U10HL080510, U10HL080413, U10HL080370, U10HL080411, U10HL080274, U10HL080371)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, warfarin, anticoagulation, coagulation cascade, mortality, hospitalization, forced vital capacity decline, international normalized ratio, blinding, early trial termination
MeSH terms
Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Warfarin, Treatment Failure, International Normalized Ratio, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.201202-0314oc
The paper
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A. (2012). A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201202-0314oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.